CRVS · Corvus Pharmaceuticals Inc
United States · RS rating 24 · As of 2026-11-03
| Price | 9.83 USD |
|---|---|
| 1-day change | +1.3% |
| RS rating (overall / 1M / 3M / 12M) | 24 / 38 / 21 / 70 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 25 / 28 / 30 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -25.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +61.5% |
| Market cap (USD) | $1.3B |